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OBJECTIVES The purpose of this study was to evaluate whether plasma aldosterone (ALD) is extracted or
produced through the heart in patients with acute myocardial infarction (AMI) and to
determine the relationship between transcardiac extraction of plasma ALD and left
ventricular (LV) remodeling.
BACKGROUND Although we demonstrated that circulating ALD was extracted through the failing heart and
that transcardiac extraction of ALD correlated with LV end-diastolic volume index
(LVEDVI) in patients with congestive heart failure, the existence and increase of ALD
synthase in the hearts of infarct rats were reported, suggesting cardiac production of ALD in
patients with AMI.
METHODS We measured plasma ALD in the aortic root (Ao) and coronary sinus (CS) in 57 consecutive
patients who received successful revascularization and enalapril, with first AMI at acute phase
and after one month. We also measured plasma procollagen type III aminoterminal peptide
(PIIINP) in the CS.
RESULTS Plasma ALD was significantly lower in the CS than it was in the Ao at the acute phase
(84.7  6.3 pg/ml vs. 105.5  8.0 pg/ml, p  0.0001). Significant positive correlations exist
between the transcardiac gradient of ALD at the acute phase and the LVEDVI at one month.
Moreover, the transcardiac gradient of plasma ALD at the acute phase has a significant correlation
with plasma PIIINP, a biochemical marker of fibrosis, after one month. Stepwise multivariate
analysis showed that transcardiac extraction of plasma ALD at the acute phase had an
independent and significant positive relationship with a large LVEDVI after one month.
CONCLUSIONS These results indicate that plasma ALD is extracted through the heart in patients with AMI
at the acute phase and that the extracted ALD plays an important role in modulating
post-infarct LV remodeling. (J Am Coll Cardiol 2001;38:1375–82) © 2001 by the American
College of Cardiology
Serial changes in the left ventricular (LV) volume and shape
described as LV remodeling affect LV function and have
been demonstrated to be important predictors of mortality
and morbidity after acute myocardial infarction (AMI) (1).
Previous studies reported that LV remodeling is regulated
by multiple components, such as mechanical, neurohor-
monal and therapeutic factors (2,3).
Aldosterone (ALD) displays both myocardial and renal
effects that may have profound implications for LV remod-
eling (4). Increased plasma ALD levels were demonstrated
to be associated with increased LV mass in patients with
hypertension as well as in a population-based sample (5–7).
In the Randomized Aldactone Evaluation Study (RALES),
the ALD receptor antagonist spironolactone was shown to
reduce the mortality of patients with congestive heart failure
(CHF) (8). Moreover, the substudy of RALES demon-
strated that the beneficial outcome in RALES might
combine with the effect of spironolactone to suppress
cardiac collagen synthesis (9). Furthermore, ALD levels
have been found to be increased in some patients with
myocardial infarction (MI) with profound implications for
cardiac remodeling and long-term prognosis (10,11). More-
over, we recently demonstrated that the suppression of
plasma ALD during the acute phase of AMI prevented
post-infarct LV remodeling (12). Modena et al. (13) re-
ported that combination therapy with an angiotensin-
converting enzyme (ACE) inhibitor and an ALD receptor
antagonist nine days after onset of AMI could prevent LV
remodeling compared with an ACE inhibitor alone. These
results suggested that endogenous ALD and a mineralocor-
ticoid receptor may play important roles in the progression
of post-infarct LV remodeling.
We reported that plasma ALD was extracted through the
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heart in patients with chronic CHF (14) and that the
transcardiac gradient of plasma ALD was correlated with
LV end-diastolic volume index (LVEDVI) and plasma
levels of procollagen type III aminoterminal peptide (PII-
INP), a marker of myocardial fibrosis (15), including pa-
tients with MI after more than three months. However, the
cause and effect of the relation between the transcardiac
gradient of plasma ALD and LVEDVI remain unknown
because we could not repeatedly measure these parameters.
Recently, it has been reported that the mineralocorticoid
receptor, which mediates the action of ALD, is expressed in
cardiomyocytes, endothelial cells and fibroblasts in the
human heart (16–19). In addition, the existence and the
increase of ALD synthase in rats with infarcted hearts has
been reported (20), suggesting the possibility of cardiac
production of ALD in patients with AMI. However,
whether plasma ALD is extracted or produced through the
heart in patients with AMI has not yet been elucidated.
Therefore, in this study we evaluated: 1) whether plasma
ALD is extracted or produced through the heart during the
acute phase, and 2) if plasma ALD is extracted, whether the
transcardiac extraction of plasma ALD during the acute
phase is related to LV remodeling in patients with AMI.
METHODS
Study population. We prospectively studied 64 patients
with first MI. Admission criteria was the same as previously
reported (12). Patients who had prior MI, significant
stenosis of an infarct-nonrelated coronary artery and resid-
ual stenosis (70%) of an infarct-related coronary artery
were excluded from this study.
Patients were classified into the high-extraction group or
the low-extraction group, based on the transcardiac extrac-
tion of ALD. The cutoff level was the median value for
transcardiac extraction of ALD at the acute phase.
All patients gave informed consent, and the study was
approved by the Committee on Human Investigation at our
institution.
Study design and protocol. All patients underwent cardiac
catheterization by the femoral approach. The infarct-related
artery was visualized in five views with contrast injections.
Patients with persistent occlusion of the infarct-related
vessel underwent percutaneous transluminal coronary an-
gioplasty after standard techniques. The patients who could
not obtain less than 70% patency and/or Thrombolysis In
Myocardial Infarction (TIMI) flow grade 3 were excluded
from this study.
After obtaining revascularization (patency 70% and
TIMI flow grade 3) and assuring hemodynamic stability,
right-sided cardiac catheterization using a 7F Swan-Ganz
catheter and measurement of LV end-diastolic pressure
using a 5F pig tail catheter were performed.
Blood samples for measuring plasma ALD were collected
simultaneously from the aortic root (Ao) and coronary sinus
(CS) as previous reported (14). Blood samples for measuring
the plasma levels of PIIINP were drawn from the CS. After
angioplasty and blood sampling were done, contrast left
ventriculography was performed.
After admission to the coronary care unit, all patients
received oral aspirin and/or ticlopidine. Angiotensin-
converting enzyme inhibitors (enalapril) were adminis-
trated to all patients. If required, oral nitrates, calcium
antagonists, beta-adrenergic blocking agents and/or di-
uretics were added and continued. However, ALD recep-
tor antagonists such as spironolactone were prohibited in
this study.
Repeat cardiac catheterization and contrast left ventricu-
lography were performed one month after the initial cath-
eterization to determine culprit artery patency and LV
function. Left ventriculography performed by contrast me-
dium were analyzed for LV ejection fraction (LVEF) and
LV volume by cardiologists who were unaware of the
patients’ data at the acute phase and after one month. Left
ventricular ejection fraction was calculated by the area-
length method. Hemodynamic measurement by Swan-
Ganz catheter and blood sampling from the Ao and CS
were also performed. Patients with significant restenosis
(70%) of the culprit lesion were excluded from the study.
Measurement of neurohumoral factors. Plasma concen-
trations of atrial natriuretic peptide and brain natriuretic
peptide were measured with a specific immunoradiometric
assay using a commercial kit (Shionogi, Osaka, Japan) as
previously reported (21). Plasma ALD levels were measured
using a commercial radioimmunoassay kit, and plasma levels
of PIIINP were measured with a specific immunoradiomet-
ric assay using a commercial kit (CIS Bio International,
Nagoya, Japan) as previously reported (14).
Statistical analysis. All results are expressed as the mean
SEM. Categoric data were compared against a chi-squared
distribution. Student t test was used for continuous variables
between groups, and paired t test was used for within-group
comparison. Linear regression analysis was used to deter-
mine the relation between continuous variables. To evaluate
the contribution of ALD extraction at the acute phase to
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
ALD  aldosterone
AMI  acute myocardial infarction
Ao  aortic root
CHF  congestive heart failure
CK  creatine phosphate
CS  coronary sinus
LV  left ventricular
LVEDVI  left ventricular end-diastolic volume index
LVEF  left ventricular ejection fraction
LVESVI  left ventricular end-systolic volume index
MI  myocardial infarction
PIIINP  procollagen type III aminoterminal peptide
RALES  Randomized Aldactone Evaluation Study
TIMI  Thrombolysis In Myocardial Infarction
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LVEDVI one month after onset, univariate and stepwise
multivariate analysis were used among the 12 variables. A p
value of 0.05 was considered significant.
RESULTS
Clinical characteristics. Sixty-four consecutive patients
who met the entry criteria were enrolled (Table 1). One
patient died of lethal arrhythmia; two died of CHF. Four
patients were excluded from this study due to restenosis of
the culprit coronary artery. Therefore, 57 of 64 patients
enrolled in the trial completed the entire protocol. There
were no differences in baseline characteristics including
infarct lesion, in-hospital therapy and the dose of ACE
inhibitor (enalapril). However, maximum creatine phos-
phate (CK) was significantly higher in the high-extraction
group than it was in the low-extraction group.
Difference between plasma concentration of ALD in the
Ao and the CS. In 57 consecutive patients with AMI,
plasma ALD at the acute phase was significantly lower in
the CS than it was in the Ao (84.7  6.3 pg/ml vs. 105.5 
8.0 pg/ml, p  0.0001) (Fig. 1). One month after onset,
plasma ALD was also significantly lower in the CS com-
Figure 1. Plasma aldosterone (ALD) concentrations at the acute phase in the aortic root (Ao) and coronary sinus (CS) in patients with acute myocardial
infarction (AMI). (Left) ALD data in all 57 patients with AMI; (Middle) ALD data in 28 patients in the high-extraction group; (Right) ALD data in
29 patients in the low-extraction group.
Table 1. Patient Characteristics
Low-Extraction
Group (n  29)
High-Extraction
Group (n  28)
p
Value
Age (yrs) 64.9  1.7 60.4  2.6 NS
Gender (male/female) 22/7 24/4 NS
Infarct lesion (anterior/lateral/inferior) 18/7/4 19/5/4 NS
Symptom onset-reflow time (h) 5.4  1.0 5.9  1.0 NS
Max CK (IU/ml) 2,037  296 3,534  378 0.003
Collateral (grade 2) 6 3 NS
Killip (2) 2 3 NS
Risk factors
Smoking 21 19 NS
Hypertension 9 12 NS
Hyperlipidemia 14 10 NS
Diabetes mellitus 9 11 NS
Acute therapy
Intravenous nitroglycerin 25 23 NS
Catecholamine 5 8 NS
IABP 3 4 NS
In-hospital therapy
Oral nitrates 19 17 NS
Ca antagonists 10 7 NS
Diuretics 1 2 NS
Beta-blockades 9 11 NS
ACE inhibitor (enalapril) dose (mg) 6.5  0.47 6.8  0.46 NS
ACE  angiotensin-converting enzyme; Ca  calcium; CK  creatine phosphokinase; IABP  intraaortic balloon pumping.
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pared with that in the Ao (46.2  2.9 pg/ml vs. 59.8 
3.5 pg/ml, p  0.0001).
Hemodynamic parameters and LV function and volume.
At the acute phase, mean pulmonary arterial pressure, mean
right atrial pressure and pulmonary capillary wedge pressure
were significantly higher in the high-extraction group com-
pared with that in the low-extraction group (Table 2). One
month after onset, there were no significant differences
between the two groups in all hemodynamic parameters.
Regarding LV function and volumes at the acute phase,
there were no significant differences in LVEF, LVEDVI
and LV end-systolic volume index (LVESVI). However,
after one month, the LVEF was significantly lower in the
high-extraction group compared with that in the low-
extraction group, and LVEDVI and LVESVI were signif-
icantly higher in the high-extraction group than they were
in the low-extraction group. The absolute change in
LVEDVI was significantly higher in the high-extraction
group than it was in low-extraction group.
Neurohumoral factors and plasma PIIINP. The plasma
ALD level in Ao at the acute phase and after one month
were significantly higher in the high-extraction group and in
the low-extraction group (Table 3). The transcardiac ALD
extraction at the acute phase and after one month were also
significantly higher in the high-extraction group compared
with those in the low-extraction group. The plasma PIIINP
level in the CS after one month was significantly higher in
the high-extraction group compared with that in the low-
extraction group, while there was no significant difference
observed at the acute phase.
Relationship of plasma ALD extraction across the heart
and LV remodeling. There was a significant positive cor-
relation between the transcardiac extraction of ALD at the
acute phase and the LVEDVI after one month (Fig. 2).
Moreover, there was also a significant positive correlation
between the transcardiac extraction of ALD at the acute
phase and the absolute change in LVEDVI (Fig. 2). There
was a significant positive correlation between the transcar-
diac extraction of ALD at the acute phase and the plasma
level of PIIINP in CS after one month (Fig. 3), and there
was also a significant positive correlation between the
plasma level of PIIINP in CS and LVEDVI after one
month (Fig. 3).
Figure 4 shows the significant positive correlation be-
tween the plasma level of ALD in the Ao at the acute phase,
the transcardiac extraction of ALD at the acute phase (r 
0.735, p  0.0001) and the transcardiac extraction of ALD
after one month (r  0.539, p  0.0001).
Table 4 shows the results of univariate and multivariate
analysis among 12 variables related to the acute phase to
assess factors regulating LVEDVI one month after onset.
According to stepwise multivariate analysis, only a high
Table 2. Hemodynamics and LV Function at the Acute Phase
and After One Month
Low-Extracted
Group
(n  29)
High-Extracted
Group
(n  28)
p
Value
Hemodynamics
Heart rate (beats/min)
Acute 72.8  2.7 79.3  3.7 NS
1 month 66.3  1.8 68.6  2.7 NS
MBP (mm Hg)
Acute 93.2  2.6 95.9  3.2 NS
1 month 87.1  2.6 89.4  2.4 NS
MPA (mm Hg)
Acute 17.1  1.0 21.1  1.2 0.015
1 month 12.9  0.7 13.0  0.5 NS
RA (mm Hg)
Acute 4.0  0.3 6.7  1.1 0.022
1 month 3.0  0.3 2.9  0.3 NS
PCWP (mm Hg)
Acute 15.1  0.9 18.5  1.3 0.036
1 month 7.4  0.5 8.0  0.5 NS
LVEDP (mm Hg)
Acute 17.3  1.0 19.4  1.0 NS
1 month 10.3  0.8 10.6  0.4 NS
Cardiac index (l/min/m2)
Acute 2.58  0.08 2.53  0.10 NS
1 month 2.91  0.09 2.83  0.11 NS
LV Function
LVEF (%)
Acute 47.7  0.9 45.8  1.4 NS
1 month 54.6  1.7 50.3  1.1 0.040
Absolute change 6.93  1.32 4.57  1.32 NS
LVEDVI (ml/m2)
Acute 86.0  2.0 88.4  2.2 NS
1 month 92.5  4.2 119.6  5.7 0.0003
Absolute change 6.48  3.75 31.3  5.61 0.0005
LVESVI (ml/m2)
Acute 45.2  1.5 48.3  2.1 NS
1 month 43.7  3.6 60.7  3.9 0.0023
Absolute change 1.57  2.86 12.4  3.68 0.0041
Absolute change  (value at one month)  (value at acute phase); LVEDP  left
ventricular end-diastolic pressure; LVEDVI  left ventricular end-diastolic volume
index; LVEF  left ventricular ejection fraction; LVESVI  left ventricular
end-systolic volume index; MBP  mean blood pressure; MPA  mean pulmonary
arterial pressure; PCWP  pulmonary capillary wedge pressure; RA  mean right
atrial pressure.
Table 3. Neurohumoral Factors
Low-Extraction
Group
(n  29)
High-Extraction
Group
(n  28)
p
Value
ANP level at Ao (pg/ml)
Acute 104.5  34.3 92.3  20.8 NS
1 month 57.1  10.3 73.4  13.1 NS
BNP level at Ao (pg/ml)
Acute 97.3  20.4 87.7  23.9 NS
1 month 71.1  15.1 105.1  16.6 NS
ALD extraction (pg/ml)
Acute 5.93  1.62 36.1  2.89 0.0001
1 month 9.52  1.81 17.7  2.48 0.0098
ALD level at Ao (pg/ml)
Acute 61.6  7.05 150.9  8.12 0.0001
1 month 51.0  4.73 68.8  4.79 0.0098
PIIINP level at CS (U/ml)
Acute 0.41  0.02 0.40  0.02 NS
1 month 0.47  0.02 0.54  0.02 0.0321
ALD  aldosterone; ANP  atrial natriuretic peptide; Ao  aortic root; BNP 
brain natriuretic peptide; CS  coronary sinus; PIIINP  procollagen type III
aminoterminal peptide.
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level of transcardiac extraction of ALD at the acute phase
(p  0.0001), a high level of maximum CK (p  0.0010)
and poor performance of LVEF at the acute phase (p 
0.0168) were significant independent predictors of a large
LVEDVI after one month.
DISCUSSION
The results of this study provide the first evidence that: 1)
plasma ALD is extracted through the heart at the acute
phase of AMI, 2) the transcardiac gradient of plasma
ALD at the acute phase correlates with the LVEDVI and
plasma levels of PIIINP one month after onset. These
results indicate that ALD is extracted through the heart
and ALD extraction stimulates LV remodeling in pa-
tients with AMI.
Plasma ALD difference between the Ao and CS in
patients with AMI. Recently, it has been shown that the
mineralocorticoid receptor, which mediates the action of
ALD, is expressed in the human heart (16–19). Although
ALD synthase was not detected in the autopsy sample of
normal subjects (19), the existence and upregulation of
ALD synthase in the heart was reported in rats with MI,
suggesting cardiac production of ALD in patients with
AMI. However, whether plasma ALD is extracted or
produced through the heart in patients with AMI has not
been yet elucidated. In this study, we demonstrated for the
Figure 2. (Left) The correlation between the transcardiac gradient of aldosterone (ALD) at the acute phase and the left ventricular end-diastolic volume
index (LVEDVI) one month after onset in patients with acute myocardial infarction. (Right) The correlation between the transcardiac gradient of ALD
at the acute phase and the difference in LVEDVI between one month and the acute phase (absolute change). Ao  aortic root; CS  coronary sinus.
Figure 3. Correlation between the plasma levels of procollagen type III aminoterminal peptide (PIIINP) one month after onset and the transcardiac
gradient of aldosterone (ALD) at the acute phase (left) and left ventricular end-diastolic volume index (LVEDVI) after one month in patients with acute
myocardial infarction (right). Ao  aortic root; CS  coronary sinus.
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first time that plasma ALD is extracted through the heart at
the acute phase of AMI. We previously reported (14) that
about 20% of the plasma ALD level was extracted between
the Ao and the CS in patients with CHF, including
previous MI more than three months after the onset. This
study showed that the ALD extraction ratio through the
heart was about 17% and 20% at the acute phase and at one
month, respectively. Taken together with our previous
study, ALD extraction through the heart was sustained
from the acute stage to the chronic stage of MI. Although
our findings did not deny the possibility of local ALD
production in the heart in patients with AMI, the predom-
inant extraction of ALD was shown because the transcar-
diac gradient of ALD reflects the total net of ALD
extraction and production through the heart. Silvestre et al.
(20) reported that both ALD synthase messenger RNA and
ALD level increased by 2- to 3.7-fold in the ventricle of rats
with MI, while plasma ALD level was not increased
compared with that in sham-operated rat. Therefore, local
production of ALD in the heart may not be sufficient to
increase the plasma ALD level, which is consistent with our
findings.
Transcardiac extraction of ALD and LV remodeling in
patients with AMI. In this study, we demonstrated a
significant positive correlation of the transcardiac ALD
gradient at the acute phase with LVEDVI after one month
and the absolute change in LVEDVI in patients with AMI,
indicating that circulating ALD is extracted through the
heart and promotes cardiac fibrosis and collagen synthesis
via the mineralocorticoid receptor in these patients.
Left ventricular remodeling was shown to be regulated by
multiple factors, including mechanical, neurohumoral and
therapeutic factors (2,3). According to stepwise multivariate
analysis, only a high transcardiac gradient of plasma ALD at
the acute phase, high levels of maximum CK and poor
LVEF at the acute phase among the 12 acute phase
variables were significant independent predictors of a large
LVEDVI at one month, suggesting that extraction of ALD,
at least at the acute phase, as well as infarct size play a
significant role in modulating LV remodeling after AMI.
With regard to therapy during the acute to subacute period,
there was no difference between the two groups in thera-
peutic strategy, including mechanical support or use of
drugs including the dose of ACE inhibitor. In this study, all
patients received revascularization therapy and oral ACE
inhibitor administration, which have been shown to prevent
LV remodeling after AMI (22,23).
Figure 4. (Left) The correlation between the plasma level of aldosterone (ALD) in the aortic root (Ao) at the acute phase and the transcardiac gradient
of plasma ALD at the acute phase in a patient with acute myocardial infarction (AMI). (Right) The correlation between the transcardiac gradient of ALD
at the acute phase and one month after onset in patients with AMI. CS  coronary sinus.
Table 4. Univariate and Multivariate Linear Model of LVEDVI
One Month After Onset in 57 Patients With AMI
Variable
Univariate
Correlation
Coefficient
p
Value
Multivariate
Beta
Coefficient
p
Value
Age (yrs) 0.008 0.9529
ANP in Ao (pg/ml) 0.056 0.6788
BNP in Ao (pg/ml) 0.209 0.1179
ALD in Ao (pg/ml) 0.461 0.0003
(Ao-CS) ALD (pg/ml) 0.656 0.0001 0.769 0.0001
Max CK (IU/dl) 0.604 0.0001 0.005 0.0010
Mean blood pressure
(mm Hg)
0.176 0.1912
Cardiac index (l/min/m2) 0.013 0.9229
PCWP (mm Hg) 0.273 0.0402
LVEDP (mm Hg) 0.328 0.0127
LVEF (%) 0.427 0.0009 1.046 0.0168
LVEDVI (ml/m2) 0.330 0.0121
All variables were measured at the acute phase.
ALD  aldosterone; ANP  atrial natriuretic peptide; Ao  aortic root; BNP 
brain natriuretic peptide; CK  creatine phosphate; LVEDP  left ventricular
end-diastolic pressure; LVEDVI  left ventricular end-diastolic volume index;
LVEF  left ventricular ejection fraction; PCWP  pulmonary capillary wedge
pressure.
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Relation between ALD extraction and plasma PIIINP in
patients with AMI. Changes in PIIINP that have been
shown to be induced by AMI in humans may reflect both
synthesis and degradation of collagen (15,24). Aldosterone
inhibition has been shown to reduce post-infarction colla-
gen synthesis and progressive LV dilation in patients with
subacute MI (13). We found a positive correlation in
patients with AMI between transcardiac ALD extraction at
the acute phase and the plasma PIIINP level in CS one
month after onset. Previous findings that ALD stimulated
collagen synthesis in isolated fibroblasts (25) and that
PIIINP is a biochemical marker of myocardial fibrosis (15)
support our results. In addition, plasma PIIINP after one
month was significantly higher in the high-extraction group
than it was in the low-extraction group, suggesting that
ALD extraction promotes ventricular fibrosis. Furthermore,
high levels of plasma PIIINP, in relation to ventricular
fibrosis, were reported to be associated with poor LV
function, remodeling and prognosis (15,26), also supporting
our data.
Therefore, our hypothesis, that the sustained extraction
of ALD is an important modulator of the progression of
post-infarct LV remodeling, is supported not only by the
hemodynamic parameters but also biochemical markers.
Clinical implications. We demonstrated that transcardiac
extraction of plasma ALD at the acute phase correlates with
LVEDVI after one month of onset and that plasma ALD
extraction at the acute phase also correlates with plasma
levels of ALD in the Ao at the acute phase. Therefore, it
would be possible to predict the magnitude of LV remod-
eling by measuring the plasma ALD level. The effect of
ALD on cardiac fibrosis was shown to be a direct effect of
ALD interacting with mineralocorticoid receptors located
on cardiomyocytes (18) or an indirect effect mediated by
upregulation of angiotensin II receptors (27). In this study,
all the patients were administered ACE inhibitors; there-
fore, most of the effect of ALD on LV remodeling in this
study is considered to be an effect conveyed via mineralo-
corticoid receptors. Moreover, the acute expansion of the
infarct region of the LV wall is reported to occur within one
week. Taken together with this study, our findings suggest
that administration of the mineralocorticoid receptor antag-
onist immediately after AMI is useful in combination with
ACE inhibitors to prevent post-infarct LV remodeling.
Study limitations. Patients with multivessel disease and
prior MI were excluded from this study. This study also
excluded patients with restenosis of the culprit lesion
because significant stenosis (70%) might reduce coronary
flow and perfusion. To verify the effect of ALD extraction
under such complex conditions, further studies are needed.
Being unable to measure the total amount of ALD extrac-
tion because the CS flow was not measured is also a
limitation of this study. Further studies are needed to
evaluate how the amount of ALD extraction affects LV
performance.
Conclusions. In patients with AMI, plasma ALD at the
acute phase was significantly lower in the CS than it was in
the Ao, suggesting ALD extraction across the heart. The
transcardiac gradient of plasma ALD at the acute phase was
correlated with the plasma levels of PIIINP and LVEDVI
one month after onset. Moreover, transcardiac ALD extrac-
tion at the acute phase affected LVEDVI after one month,
independent of infarct size. These findings suggest that
elevated transcardiac ALD extraction through the heart
plays an important role in the regulation of post-infarct LV
remodeling in patients with AMI.
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